Kaplan-Meier analysis and Cox proportional regression modeling were used to assess overall survival (OS).

FOXP3 expression in breast cancer cells: a new predictor of response to anthracyline versus docetaxel in primary breast cancer treated with adjuvant chemotherapy in the Phase III trial FNCLCC/PACS 01.

Francois Ghiringhelli1,2, Pierre Fumoleau1, Gregory Mignot2, Laurent Arnould1, Henri Roché3, Marc Spielmann4, Christelle Levy5, Françoise Eichler7, Christel Mesleard8, Sylvain Ladoire1,2

Patients and Methods

PACS01 is a study that compared in node positive breast cancer the effect of adjuvant anthracyline regimen (6 cycle of FEC100) versus the sequential treatment with anthracyline followed by taxane (3FEC100 and 3 docetaxel 100). For this study that included 1999 patients a tumor collection was made for 1190 patients. We could obtain material sufficient material for 1097 patients. We studied by a tumor collection was made for 1190 patients. We could obtain material sufficient material for 1097 patients. We studied by

Patients and Methods

Background

Results

In conclusion, up to our knowledge, this study may provide the first biomarker of sensitivity to anthracyline. In addition this study propose a rational to test HDAC inhibitors and especially valproate acid to enhance sensitivity of Foxp3 negative breast cancer to anthracyline regimens.